Prior to joining AlloVir, Dr. Melian was an SVP in both Global Clinical Development and Medical Sciences at Alexion Pharmaceuticals. During his tenure there, the company achieved record timelines across clinical development including Ultomiris (a >500 patients rare disease development program fully executed from Investigational New Drug (IND) application to filing in
Dr. Melian has a background in DNA transcription and repair. Prior to his industry work, he practiced medicine and conducted Basic Immunology Research at The Brigham and Women’s Hospital in Boston. Dr. Melian graduated cum laude with degrees in Molecular Biophysics and Biochemistry and in Medicine from Yale University.